Annexon Biosciences: ANX005 Antibody Shines in Phase 3 Trials For Treatment Of Guillain-Barré Syndrome
ANX005 led to significant reductions in GBS-associated disability, improved muscle power, reduced nerve damage, and a reduced need for mechanical ...
